Clinical Trials Browser

Phase 2 × INDUSTRY × Urethral Neoplasms × Clear all

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

219 enrolled 32 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Phase 2 Completed

148 enrolled 19 charts

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Phase 2 Terminated

142 enrolled 13 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

NCT00661609 2011-01-12

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Phase 2 Completed

54 enrolled 10 charts

Urinary Bladder Neoplasms, Recurrence, Ureteral Neoplasms, Urethral Neoplasms

NCT00077688 2009-06-04

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms